CPL2 Antibody

Introduction to cPLA2 Antibody

cPLA2 (cytosolic phospholipase A2 group IVA) antibodies are critical tools for studying the enzyme’s role in lipid signaling and inflammation. cPLA2 catalyzes the hydrolysis of phospholipids at the sn-2 position to release arachidonic acid (AA), a precursor for eicosanoids like prostaglandins and leukotrienes . These antibodies enable detection of cPLA2 in research models, aiding investigations into inflammatory diseases, cancer, and metabolic disorders .

Research Findings and Functional Insights

• Role in Inflammation: cPLA2 activation requires phosphorylation at Ser-505 and Ser-727, triggered by elevated cytosolic Ca²⁺ . This facilitates its translocation to perinuclear membranes, initiating AA release .

• Autoimmune Regulation: In macrophages and neutrophils, cPLA2-derived eicosanoids modulate immune responses, linking it to diseases like rheumatoid arthritis .

• Gene Knockout Studies: cPLA2-deficient mice show reduced inflammatory responses, underscoring its therapeutic targeting potential .

Antibody Validation and Specificity

cPLA2 antibodies undergo rigorous validation:

• Western Blot: Detects endogenous cPLA2 at ~85–95 kDa in human, mouse, and rat lysates .

• Immunohistochemistry: Validated in human thyroid cancer and brain tissues .

• Cross-Reactivity: Predictions suggest reactivity with bovine, horse, and dog homologs (score >80) .

Validation Table

Post-Translational Modifications and Enzyme Activation

cPLA2 activity is regulated by phosphorylation and ubiquitination:

Clinical and Research Implications

• Cancer: Overexpression in tumors correlates with AA-driven proliferation and metastasis .

• Cardiovascular Disease: cPLA2 inhibitors reduce atherosclerosis in preclinical models .

• Therapeutic Targeting: Small-molecule cPLA2 inhibitors (e.g., AVX001) are in clinical trials for autoimmune diseases .